| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, University Hospital W-587, Indiana University Medical School, Indianapolis, Indiana 46223 [D. E. S.], and Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285 [C. J. K., S. M. R., H. L. P.]
The systemic use of thiol-containing uroepithelial protecting agents, e.g., N-acetylcysteine (NAC) or mesna, in conjunction with the alkylating agent cyclophosphamide is predicated on the assumption that the toxic metabolic by-products will be consumed by thiol without diminishing the cytotoxicity of the active alkylating intermediate, phosphoramide mustard. Studies in murine tumor systems have been with either a single dose or two equally divided doses of thiol, administered within 30 min of the addition of cyclophosphamide, without an observed adverse effect on antitumor activity; however, the realtively short serum half-life of thiol relative to alkylating agent in humans weakens the clinical relevance of these results. This study presents a thermodynamic model for the chemical reaction of phosphoramide mustard with either NAC or mesna. The gas phase thermodynamic parameters for these reactions, enthalpy (H) and entropy (S), were calculated using the semiempirical quantum mechanical method AM1 and were used to predict the free energy (
G) for these processes. For the reaction of phosphoramide mustard with NAC or mesna,
G = +3.82 and 2.29 kcal/mol, respectively. In the absence of enzyme catalysis, these results suggest that such reactions are not favored. In order to assess the validity of this gas phase thermodynamic model, the cellular cytotoxicity of phosphoramide mustard in the presence or absence of either NAC or mesna was studied using CCRF-CEM cells in culture. In these experiments the 50% effective dose of phosphoramide mustard was 1.7 µg/ml; this result was unchanged in the presence of 10 µg/ml concentration of either thiol. This study supports the conclusion that phosphoramide mustard and protector thiols are compatible.
1 Presented in part at the 1988 Meeting of the American Association for Cancer Research.
2 To whom requests for reprints should be addressed, at Department of Medicine, University Hospital W-587, Indiana University Medical School, 926 West Michigan St., Indianapolis, IN 46223.
Received 12/ 5/88. Revised 3/27/89. Accepted 4/ 4/89.
This article has been cited by other articles:
![]() |
K. A. Tacka, J. C. Dabrowiak, J. Goodisman, and A.-K. Souid Kinetic Analysis of the Reactions of 4-Hydroperoxycyclophosphamide and Acrolein With Glutathione, Mesna, and Wr-1065 Drug Metab. Dispos., August 1, 2002; 30(8): 875 - 882. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-K. Souid, R. C. Fahey, M. K. Aktas, O. A. Sayin, S. Karjoo, G. L. Newton, P. D. Sadowitz, R. L. Dubowy, and M. L. Bernstein Blood Thiols Following Amifostine and Mesna Infusions, a Pediatric Oncology Group Study Drug Metab. Dispos., November 1, 2001; 29(11): 1460 - 1466. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |